Philina Lee
Director/Board Member chez FUSN PHAR
Fortune : 3 M $ au 31/03/2024
Profil
Philina Lee is an Independent Director at Fusion Pharmaceuticals, Inc. since 2021.
She is also the Chief Commercial Officer at Blueprint Medicines Corp.
since 2014.
Previously, she worked at Algeta ASA as the Head-US Marketing.
Dr. Lee holds a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of Alberta.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
13/03/2024 | 34 729 ( 0,06% ) | 3 M $ | 31/03/2024 | |
14/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Philina Lee
Sociétés | Poste | Début |
---|---|---|
FUSN PHAR | Director/Board Member | 11/02/2021 |
BLUEPRINT MEDICINES CORPORATION | Corporate Officer/Principal | 01/01/2021 |
Anciens postes connus de Philina Lee
Sociétés | Poste | Fin |
---|---|---|
ALGETA ASA | Corporate Officer/Principal | - |
Formation de Philina Lee
Massachusetts Institute of Technology | Doctorate Degree |
University of Alberta | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
BLUEPRINT MEDICINES CORPORATION | Health Technology |
FUSN PHAR | Health Technology |
Entreprise privées | 1 |
---|---|
Algeta ASA
Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |